Drug Trial Radar · NCT07761286
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Sep 30, 2029
Study completion Sep 30, 2031
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).
Conditions
- HCC - Hepatocellular Carcinoma
Interventions
SYS6090 Injection + Bevacizumab InjectionDrug
SYS6090 in Combination with Bevacizumab 15mg/kg
SYS6090 Injection +SYS6043 Injection +Bevacizumab InjectionDrug
SYS6090 in Combination with SYS6043 and Bevacizumab 15mg/kg
Bevacizumab Injection + Sintilimab InjectionDrug
Bevacizumab 15mg/kg in Combination with Sintilimab 200mg, intravenous infusion, every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 2 years.
- Overall response rate (ORR)Time frame: Up to 2 years.
- DLT;RP2D and MTDTime frame: Up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin medical university Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.